NCT00298779已完成1 期
An Open-Label Study to Assess the Effect of Omeprazole Administration on the Pharmacokinetics of VELCADE in Subjects With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- The investigator will determine the patient's response to VELCADE treatment following completion of Cycle 2 (Day 21).
研究概览
简要总结
This is an open-label, randomized, multiple-dose, multicenter Pharmacokinetics drug-drug interaction study in patients with advanced solid tumors, including non-Hodgkin's lymphoma, who are in need of anti-tumor therapy. In addition, the impact of omeprazole on the pharmacodynamics of VELCADE will also be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1) Male or female at least 18 y/o 2)Weigh \>/= 50 kg (110lbs) and a BMI of \/= 3 mos; 4)Karnofsky Performance Status \>/=70%; 5)Women must be menopausal. 3)Men must agree to use an acceptable method of contraception for the duration of the study.4)Must sign an informed consent document indicating understanding of the purpose and procedures required for the study;5)informed consent for genetic testing 6)Subjects have advanced solid tumor (including non-Hodgkin's lymphoma).7)resolution of reversible toxicities considered related to any prior antineoplastic therapies before entry; 8)must be able to swallow capsules whole; -
排除标准
- •Prior exposure to VELCADE.2)Has known hypersensitivity or intolerance to omeprazole, boron, mannitol or heparin. 3)Medical history of of liver or renal insufficiency; significant cardiac, vascular, pulmonary, GI, endocrine, neurologic, rheumatologic, pyschiatric or metabolic disturbances. 4)Uncontrolled diabetes. 5)history of hypotension or decreased blood pressure;6)Uncontrolled or severe cardiovascular disease incl. myocardial infarction within 6 mos of enrollment; 7)History of alcohol/drug abuse. 8)Presence of HIV antibodies, hepatitis C antibodies or hepatitis B. 9)active systemic infection requiring treatment; 10)Pregnant or breastfeeding' 11)neuropathy >/= Gr.1; 12)transfusion dependence; 12)pre-planned surgeries or procedures that would interfere with conduct of study
结局指标
主要结局
The investigator will determine the patient's response to VELCADE treatment following completion of Cycle 2 (Day 21).
时间窗: completion of cycle 2 - Day 21
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive EsophagitisReflux EsophagitisNCT00859287AstraZeneca10,703
已完成
1 期
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy AdultsHepatitis CNCT01458054GlaxoSmithKline28
已完成
1 期
A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy VolunteersHealthy VolunteersNCT05497557Amgen16
已完成
1 期
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult MenHealthy VolunteersNCT01588782Janssen Research & Development, LLC20
已完成
1 期
A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT00965653Hoffmann-La Roche29